High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial-Reference-Cited by-同舟云学术

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial

Published:2022-08 Issue: Volume:170 Page:133-140
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Zwierenga Fenneke,van Veggel Bianca,Hendriks Lizza E.L.,Hiltermann T. Jeroen N.,Hiddinga Birgitta I.,Hijmering Kappelle Lucie B.M.,ter Elst Arja,Hashemi Sayed M.S.,Dingemans Anne-Marie C.,van der Leest Cor,de Langen Adrianus J.,van den Heuvel Michel M.,van der Wekken Anthonie J.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference46 articles.

1. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA - J. Am. Med. Assoc.,2014

2. The role of EGF-related peptides in tumor growth;Normanno;Front. Biosci.,2001

3. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer;Kosaka;Biol. Clin. Implic.,2004

4. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib;Lynch;N. Engl. J. Med.,2004

5. Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC;Ramalingam;New Engl. J. Med.,2020

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil;Cancers;2024-09-03

2. Current clinical practice and physicians’ insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation;BMC Cancer;2024-08-23

3. A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19);Lung Cancer;2024-08

4. The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation;Frontiers in Oncology;2024-06-11

5. SHP2 mediates STAT3/STAT6 signaling pathway in TAM to inhibit proliferation and metastasis of lung adenocarcinoma;Aging;2024-05-14